Question 1

What is Cencora's P/E ratio?

Accepted Answer

Cencora (COR) P/E ratio is 23.0× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Cencora?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Cencora specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is Cencora's P/E ratio high or low?

Accepted Answer

Cencora's P/E ratio of 23.0× is below its own 5-year average of 24.6× and below the sector median of 24.2×. That places the current reading at the 43th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Cencora's historical P/E ratio range?

Accepted Answer

In the available daily series, Cencora (COR) P/E ratio has ranged from a low of 10.4× in 2016 to a high of 562.9× in 2014. The 5-year average is 24.6× and the 5-year median is 23.0×.

Question 7

What was Cencora's P/E ratio in 2025?

Accepted Answer

Cencora (COR) P/E ratio at the end of 2025 was 39.0×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Cencora's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$60.6B	$1.55B	39.0×	+9.4×	Sep 30, 2025
2024	$44.7B	$1.51B	29.6×	+8.6×	Sep 30, 2024
2023	$36.6B	$1.75B	21.0×	+4.5×	Sep 30, 2023
2022	$28B	$1.7B	16.5×	+0.4×	Sep 30, 2022
2021	$24.8B	$1.54B	16.1×	—	Sep 30, 2021
2020	$19.8B	-$3.41B	—	—	Sep 30, 2020
2019	$17.1B	$855M	20.0×	+8.0×	Sep 30, 2019
2018	$20B	$1.66B	12.1×	-31.6×	Sep 30, 2018
2017	$18.1B	$414M	43.6×	+31.2×	Sep 30, 2017
2016	$17.7B	$1.43B	12.4×	—	Sep 30, 2016
2015	$20.2B	-$135M	—	—	Sep 30, 2015
2014	$17.3B	$276M	62.7×	+30.2×	Sep 30, 2014
2013	$14.1B	$434M	32.5×	+19.3×	Sep 30, 2013
2012	$9.47B	$719M	13.2×	-0.9×	Sep 30, 2012
2011	$9.93B	$707M	14.1×	+0.6×	Sep 30, 2011
2010	$8.55B	$637M	13.4×	+0.4×	Sep 30, 2010
2009	$6.55B	$503M	13.0×	-10.5×	Sep 30, 2009
2008	$5.89B	$251M	23.5×	+6.8×	Sep 30, 2008
2007	$7.83B	$469M	16.7×	-2.5×	Sep 30, 2007
2006	$8.99B	$469M	19.2×	-5.6×	Sep 30, 2006
2005	$8.22B	$333M	24.7×	+11.9×	Sep 30, 2005
2004	$6.01B	$468M	12.8×	-0.5×	Sep 30, 2004
2003	$5.88B	$441M	13.3×	-8.7×	Sep 30, 2003
2002	$7.59B	$345M	22.0×	—	Sep 30, 2002


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Cencora (COR) 2002-2026

P/E Ratio daily chart for Cencora (COR)

Historical P/E Ratio for Cencora (COR) from 2002 to 2025

About P/E Ratio at Cencora (COR)

Cencora P/E Ratio by Year

Cencora P/E Ratio 2025: 39.0×

Cencora P/E Ratio 2024: 29.6×

Cencora P/E Ratio 2023: 21.0×

Cencora P/E Ratio 2022: 16.5×

Cencora P/E Ratio 2021: 16.1×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Cencora (COR) Key Financials